Filing beckons as Lynparza hits the mark in adjuvant breast cancerAstraZeneca’s PARP inhibitor Lynparza has shown a clinical benefit when given as an adjuvant for early breast cancer, Share XFiling beckons as Lynparza hits the mark in adjuvant breast cancerhttps://pharmaphorum.com/news/filing-beckons-as-lynparza-hits-the-mark-in-adjuvant-breast-cancer/
Ibrance trial failure dashes Pfizer’s growth hopes for the drugPfizer already makes big revenues from its breast cancer drug Ibrance, but a late-stage trial failure has set Share XIbrance trial failure dashes Pfizer’s growth hopes for the drughttps://pharmaphorum.com/news/ibrance-trial-failure-dashes-pfizers-growth-hopes-for-the-drug/
GSK to produce a billion doses of COVID-19 vaccine booster by 2021GlaxoSmithKline is to scale up production of its COVID-19 vaccine booster to a billion doses by 2021 to support development of Share XGSK to produce a billion doses of COVID-19 vaccine booster by 2021https://pharmaphorum.com/news/gsk-to-produce-a-billion-doses-of-covid-19-vaccine-booster-by-2021/
